Seda’s Paul Dickinson took the stage at the PBBM (Physiologically Based Pharmacokinetics Modelling) Conference 2024, hosted by the MHRA and APS. The event was a fantastic opportunity for regulatory agencies, innovator and generic drug companies, consultants, academia, commercial software providers, and others in the field of oral drug product modelling and simulation to come together and explore the latest advancements in PBBM while influencing the future pathway for regulatory use.

About Paul’s Talk:
Paul’s presentation was titled: Clinically Relevant Dissolution Specifications: Implications for Use in the Post-Marketing Setting & Tension with f2 Similarity Testing. We are proud to see Paul, one of the originators of the “safe space” concept, contributing to this vital conversation. His influential paper on the Clinical Relevance of Dissolution Testing in Quality by Design has set a benchmark in our field.

Access the slides from Paul’s presentation here.

This was an inspiring event that will shape the future of biopharmaceutics!

For more details on Seda’s modelling capabilities, please click here.